|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2006-8-22
|
|
pubmed:abstractText |
Left atrial (LA) stunning, the transient impairment of LA function, is responsible for an increased thrombo-embolic risk after cardioversion of atrial fibrillation (AF). Angiotensin receptor blockers (ARBs) attenuate atrial remodelling in AF and could theoretically influence LA stunning. We studied the effect of Irbesartan on LA stunning.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0195-668X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2062-8
|
|
pubmed:meshHeading |
pubmed-meshheading:16891381-Adult,
pubmed-meshheading:16891381-Aged,
pubmed-meshheading:16891381-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:16891381-Atrial Fibrillation,
pubmed-meshheading:16891381-Atrial Function, Left,
pubmed-meshheading:16891381-Biphenyl Compounds,
pubmed-meshheading:16891381-Case-Control Studies,
pubmed-meshheading:16891381-Echocardiography,
pubmed-meshheading:16891381-Electric Countershock,
pubmed-meshheading:16891381-Female,
pubmed-meshheading:16891381-Humans,
pubmed-meshheading:16891381-Male,
pubmed-meshheading:16891381-Middle Aged,
pubmed-meshheading:16891381-Prospective Studies,
pubmed-meshheading:16891381-Tetrazoles
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation.
|
|
pubmed:affiliation |
First Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece. nikolaosdagres@yahoo.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
